Venture
Cambrian BioPharma Inc
Latest Form D 2026-07-15- CIK 1797409
- State NY
- Biotechnology
- 5 Form D offerings since 2020-01-27
- Total sold
- $272M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2020-01-27
- Latest round
- $124M
- 2026-07-15 · 021-590950
- Investors
- 80
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2026-07-15 · $124M
- 2020-01-27$4.8M021-359008
- 2021-05-06$28.4M021-398458
- 2021-12-02$92.2M021-423260
- 2023-12-22$23M021-500632
- 2026-07-15$124M021-590950
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($124M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-590950 | First filed2026-07-15 | Latest2026-07-15 | Sought$130M | Sold$124M | Investors80 | Exemptions506(c) |
| 021-500632 | First filed2023-12-22 | Latest2025-01-13 | Sought$37.6M | Sold$23M | Investors30 | Exemptions506(b) |
| 021-423260 | First filed2021-12-02 | Latest2021-12-02 | Sought$101M | Sold$92.2M | Investors56 | Exemptions506(b) |
| 021-398458 | First filed2021-05-06 | Latest2021-05-06 | Sought$28.4M | Sold$28.4M | Investors30 | Exemptions506(b) |
| 021-359008 | First filed2020-01-27 | Latest2020-01-27 | Sought$4.8M | Sold$4.8M | Investors5 | Exemptions506(b) |
Who backs Cambrian BioPharma Inc — 3 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2026-07-15
| Name | Relationship |
|---|---|
| James Peyer | RelationshipExecutive Officer, Director |
| Juliette Han | RelationshipExecutive Officer, Director |
| Mark Nuttall | RelationshipExecutive Officer |
| Ruth Thieroff-Ekerdt | RelationshipExecutive Officer |
| William DeVaul | RelationshipExecutive Officer |
| Christian Angermeyer | RelationshipDirector |
| Maryanna Saenko | RelationshipDirector |
| Brenton L. Saunders | RelationshipDirector |
| Paul Farr | RelationshipDirector |
| Martin Gunhaga | RelationshipDirector |
| Lorin Van Nuland | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- New York (NY)
- Exemptions
- Rule 506(c); Rule 506(b)
- First filed
- 2020-01-27
- Latest filing
- 2026-07-15
Who backs Cambrian BioPharma Inc
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗